Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Advanced glycation endproducts (AGEs) are a heterogeneous group of stable compounds formed through non-enzymatic reactions between reducing sugars and free amine groups on proteins, lipids, or nucleic acids. This process, known as glycation, primarily occurs via the Maillard reaction, leading to the formation of AGEs that accumulate in tissues and contribute to various pathological conditions, including diabetes, cardiovascular disease, and neurodegeneration. AGEs exert their effects by binding to receptors like RAGE, triggering inflammatory and oxidative pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Advanced Glycation Endproduct Formation.